Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion Danish ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · DK
- [CONFLICT] Maersk says ship passed through Strait of Hormuz under U.S. military protection
- [TECH] Denmark presses pause on new data center grid connections as total requests hit 60 GW — Nordic nation is the latest to put the brakes on AI buildouts
- [ENERGY] Vestas Profit Rises on Offshore Ramp-Up, Warns on Risks
- [TECH] Brett King announced as challenge speaker at EBAday 2026 in Copenhagen
- [ENERGY] Ørsted Beats First-Quarter Profit Forecasts, Keeps Outlook
- [CONFLICT] Novo Nordisk lifts forecasts after strong demand for Wegovy weight-loss pill